Company intelligence / Profile preview
Douglas Pharmaceuticals
Henderson, Auckland, New Zealanddouglas.co.nz ↗
- Ownership
- Private
- Employees
- ~700
- Development stage
- Other
01
Overview
Douglas Pharmaceuticals has multiple commercial products and ongoing clinical trials. Their R-107 Phase 2 study results for Treatment-Resistant Depression were accepted by Nature Medicine in June 2024. They are also developing R-131-2 (Lopinavir/Ritonavir) for cervical intraepithelial neoplasia in partnership with Daré Bioscience.
- Therapeutic areas
- PsychiatryEndocrinologyDermatologyWomen's HealthOncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Daré BioscienceUpsher-Smith Laboratories
Beyond the preview
Go deeper on Douglas Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Douglas Pharmaceuticals.